3770 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 9
Salomeꢀ et al.
(24) Fariello, R. G. Safinamide. Neurotherapy 2007, 4, 110–116.
(25) Errington, A. C.; Stoehr, T.; Heers, C.; Lees, G. The investigational
anticonvulsant lacosamide selectively enhances slow inactivation
of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73, 157–
169.
(26) Sheets, P. L.; Heers, C.; Stoehr, T.; Cummins, T. R. Differential
block of sensory neuronal voltage-gated sodium channels by
lacosamide[(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide],
lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 2008, 326,
89–99.
(27) Fariello, R. G.; McArtur, R. A.; Bonsignori, A.; Cervini, M. A.;
Maj, R.; Marrari, P.; Pevarello, P.; Wolf, H. H.; Woodhead, J. W.;
White, H. S.; Varasi, M.; Salvati, P.; Post, C. Preclinical evaluation
of PNU-151774E as a novel anticonvulsant. J. Pharmacol. Exp.
Ther. 1998, 285, 397–403.
promising development stage compounds. Pharmacol. Rev. 1997,
42, 223–286. (b) Aiken, S. P.; Brown, W. M. Treatment of epilepsy:
existing therapies and future developments. Front. Biosci. 2000, 5,
124–152.
(3) (a) Brodie, M. J.; Dichter, M. A. Antiepileptic drugs. N. Engl. J.
Med. 1996, 334, 168–175. (b) Dichter, M. A.; Brodie, M. J. New
antiepileptic drugs. New Engl. J. Med. 1996, 334, 1583–1590.
(4) McNamara, J. O. Pharmacotherapies of the epilepsies. In Goodman
& Gilman’s The Pharmacological Basis of Therapeutics, 11th ed.;
Brunton, L. L., Lazo, J. S., Parker, K. L., Eds.; McGraw-Hill: New York,
2006, Chapter 19, pp 501-525.
(5) (a) McCorry, D.; Chadwick, D.; Marson, A. Current drug treat-
ment of epilepsy in adults. Lancet Neurol. 2004, 3, 729–735.
(b) Duncan, J. S. The promise of new antiepileptic drugs. Br. J. Clin.
Pharmacol. 2002, 53, 123–131.
(6) Pellock, J. M.; Willmore, L. J. A rational guide to monitoring in
patients receiving anticonvulsants. Neurology 1991, 41, 961–964.
(7) Cortes, S.; Liao, Z.-K.; Watson, D.; Kohn, H. Effect of structural
modification of the hydantoin ring on anticonvulsant activity.
J. Med. Chem. 1985, 28, 601–606.
(8) Conley, J. D.; Kohn, H. Functionalized D,L-amino acid derivatives.
Potent new agents for the treatment of epilepsy. J. Med. Chem.
1987, 30, 567–574.
(28) Maj, R.; Fariello, R.; Pevarello, P.; Varasi, M.; McArthur, R. A.;
Salvati, P. Anticonvulsant activity of PNU-151774E in the amyg-
dala kindled model of complex partial seizures. Epilepsia 1999, 40,
1523–1528.
(29) Levy, R. H.; Mattson, R.; Meldrum, B. Antiepileptic Drugs,
4th ed.; Raven Press: New York, 1995; Chapter 6.
(30) Pavarello, P.; Bonsignori, A.; Caccia, C.; Amici, R.; McArthur,
R. A.; Fariello, R. G.; Salvatti, P.; Varasi, M. Sodium channel
activity and sigma binding of 2-aminopropanamide anticonvul-
sants. Bioorg. Med. Chem. Lett. 1999, 9, 2521–2524.
(9) Kohn, H.; Conley, J. D. New antiepileptic agents. Chem. Ber. 1988,
24, 231–234.
(31) Forrelatedexamplesthatusehydrid(dual) agents,see:(a)Barbachyn,
M. R. In: Annual Reports in Medicinal Chemistry, Volume 43,
Macor, J. E., Ed.; Elsevier, London, 2008; Chapter 17, pp 281-292.
(b) Yogeeswari, P.; Ragevendran, J. V.; Sriram, D.; Nageswari, Y.;
Kavya, R.; Sreevatsan, N.; Vanitha, K.; Stables, J. Discovery of
4-aminobutyric acid derivatives possessing anticonvulsant and antino-
ciceptive activities: a hybrid pharmacophore approach. J. Med. Chem.
2007, 50, 2459–2467.
(32) Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.;
Kupferberg, H. J.; Scoville, B.; White, B. G. Antiepileptic drug
development program. Cleveland Clin. Q. 1984, 51, 293–305.
(33) Anderson, G. W.; Zimmerman, J. E.; Callahan, F. M. A reinves-
tigation of the mixed carbonic anhydride method of peptide
synthesis. J. Am. Chem. Soc. 1967, 87, 5012–5017.
(10) Kohn, H.; Conley, J. D.; Leander, J. D. Marked stereospecificity in
a new class of anticonvulsants. Brain Res. 1988, 457, 371–375.
(11) Kohn, H.; Sawhney, K. N.; LeGall, P.; Conley, J. D.; Robertson,
D. W.; Leander, J. D. Preparation and anticonvulsant activity of a
series of functionalized R-aromatic and R-heteroaromatic amino
acids. J. Med. Chem. 1990, 33, 919–926.
(12) Kohn, H.; Sawhney, K. N.; LeGall, P.; Robertson, D. W.; Leander,
J. D. Preparation and anticonvulsant activity of a series of func-
tionalized R-heteroatom-substituted amino acids. J. Med. Chem.
1991, 34, 2444–2452.
(13) Kohn, H.; Sawhney, K. N.; Bardel, P.; Robertson, D. W.; Leander,
J. D. Synthesis and anticonvulsant activities of R-heterocyclic
R-acetamido-N-benzylacetamide derivatives. J. Med. Chem. 1993,
36, 3350–3360.
(34) Swamy, K. C. K.; Kumar, N. N. B.; Balaraman, E.; Kumar, K. V.
P. P. Mitsunobu and related reactions: advances and applications.
Chem. Rev. 2009, 109, 2551–2651.
(35) Maes, B. U. W.; Tapolcsanyi., P.; Meyers, C.; Matyus, P. Palladium-
catalyzed reactions on 1,2-diazines. Curr. Org. Chem. 2006, 10,
377–417.
(36) Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reac-
tions of organoboron compounds. Chem. Rev. 1995, 95, 2457–
2483.
(37) Chinchilla, R.; Najera, C. The Sonogahira reaction: a booming
methodology is synthetic organic chemistry. Chem. Rev. 2007, 107,
874–922.
(38) Kunishima, M.; Kawachi, C.; Monta, J.; Terao, K.; Iwasaki, F.;
Tani, S. 2-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium
chloride: an efficient condensing agent leading to the formation of
amides and esters. Tetrahedron 1999, 55, 13159–13170.
(39) For comparable procedures for resolving stereoisomers, see the
following: (a) Weisman, G. R. In Asymmetric Synthesis-Analytical
Methods; Morrison, J. D.; Ed.; Academic Press: New York, 1983;
Vol. 1, pp 153-171. (b) Parker, D.; Taylor, R. J. Direct 1H NMR assay
of the enantiomeric composition of amines and β-amino alcohols using
O-acetyl mandelic acid as a chiral solvating agent. Tetrahedron 1987,
43, 5431–5456.
(40) Stables, J. P.; Kupferberg, H. G. In Molecular and Cellular Targets
for Antiepileptic Drugs;: Avanzini, G., Tanganelli, P., Avoli, M., Eds.;
John Libbey: London, 1977; pp 191-198.
(41) Dunham, N. W.; Miya, T.-S. A note on a simple apparatus for
detecting neurological deficit in rats and mice. J. Am. Pharm.
Assoc. 1957, 46, 208–209.
(14) Bardel, P.; Bolanos, A.; Kohn, H. Synthesis and anticonvulsant
activities of R-acetamido-N-benzylacetamide derivatives contain-
ing an electron-deficient R-heteroaromatic substituent. J. Med.
Chem. 1994, 37, 4567–4571.
(15) Kohn, H.; Sawhney, K. N.; Robertson, D. W.; Leander, J. D.
Anticonvulsant properties of N-substituted R,R-diamino acid deri-
vatives. J. Pharm. Sci. 1994, 83, 689–691.
(16) Choi, D.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant
activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med.
Chem. 1996, 39, 1907–1916.
(17) Morieux, P.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant
activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propio-
namide derivatives. Bioorg. Med. Chem. 2008, 16, 8968–8975.
ꢀ
ꢀ
(18) Salome, C.; Salome-Grosjean, E.; Park, K. D.; Morieux, P.;
Swendiman, R.; DeMarco, E.; Stables, J. P.; Kohn, H. Synthe-
sis and anticonvulsant activities of (R)-N-(40-substituted)benzyl
2-acetamido-3-methoxypropionamides. J. Med. Chem. 2010, 53,
1288–1305.
(19) Stoehr, T.; Kupferberg, H. J.; Stables, J. P.; Choi, D.; Harris, R. H.;
Kohn, H.; Walton, N.; White, H. S. Lacosamide, a novel anti-
convulsant drug, shows efficacy with a wide safety margin in rodent
models for epilepsy. Epilepsy Res. 2007, 74, 147–154.
(20) Pevarello, P.; Bonsignori, A.; Dostert, P.; Heidempergher, F.;
Pinciroli, V.; Colombo, M.; McArthur, R. A.; Salvati, P.; Post,
C.; Fariello, R. G.; Varasi, M. Synthesis and anticonvulsant
activity of a new class of 2-[(arylalkyl)amino]alkanamide deriva-
tives. J. Med. Chem. 1998, 41, 579–590.
(21) Salvati, P.; Maj, R.; Caccia, C.; Cervini, M. A.; Fornaretto, M. G.;
Lamberti, E.; Pevarello, P.; Skeen, G. A.; White, H. S.; Wolf, H. H.;
Faravelli, L.; Mazzanti, M.; Mancinelli, M.; Varasi, M.; Fariello,
R. G. Biochemical and electrophysiological studies on the mecha-
nism of action of PNU-151774E, a novel antiepileptic compound.
J. Pharmacol. Exp. Ther. 1999, 288, 1151–1159.
(42) White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.;
Kupferberg, H. J.; Wolf, H. H. General Principles: Discovery
and Preclinical Development of Antiepileptic Drugs. In Antiepi-
leptic Drugs, 5th ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S.,
Perruca, E., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA,
2002; pp 36-48.
(22) Perucca, E.; Yasothan, U.; Clincke, G.; Kirkpatrick, P. Lacosamide.
Nat. Rev. Drug Discovery 2008, 7, 973–974.
(43) Barton, M. E.; Klein, B. D.; Wolff, H. H.; White, H. S. Pharmaco-
logical characterization of the 6 Hz psychomotor seizure model of
partial epilepsy. Epilepsy Res. 2001, 47, 217–227.
(44) Swinyard, E. A. Laboratory evaluation of antiepileptic drugs:
review of laboratory methods. Epilepsia 1969, 10, 107–119.
(45) (a) Morimoto, K.; Fahnestock, M.; Racine, R. J. Kindling and
status epilepticus models of epilepsy: rewiring the brain. Prog.
Neurobiol. 2004, 73, 1–60. (b) Lothman, E. W.; Williamson, J. M.
(23) (a) Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.;
Curatolo, L.; Salvati, P.; Fariello, R. G. Safinamide: From mole-
cular targets to a new anti-Parkinson drug. Neurology 2006, 67
(7, Suppl. 2), S18–S23. (b) Merck Serono’s Safinamide Significantly
Improved Motor Function in Patients with Advanced Parkinson’s
Disease in a Phase III Pivotal Trial; Merck Serono: Geneva, February
20090203_en_tcm112_35396.pdf.